List of Excipients in Branded Drug GASTROGRAFIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bracco Diagnostics Inc	GASTROGRAFIN	diatrizoate meglumine and diatrizoate sodium	0270-0445	EDETATE DISODIUM
Bracco Diagnostics Inc	GASTROGRAFIN	diatrizoate meglumine and diatrizoate sodium	0270-0445	SACCHARIN SODIUM
Bracco Diagnostics Inc	GASTROGRAFIN	diatrizoate meglumine and diatrizoate sodium	0270-0445	SODIUM CITRATE

Gastrografin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Gastrografin is an iodinated gastrointestinal contrast medium containing diatrizoate meglumine and diatrizoate sodium. Its commercial opportunity is not primarily a new-molecule patent play. The stronger opportunities are generic or alternative-source manufacturing, excipient supply, palatability improvements, ready-to-use presentations, hospital supply resilience, and regulatory support for equivalent products.

The U.S. formulation uses a relatively short excipient system: edetate disodium, polysorbate 80, sodium saccharin, and water for injection. Each excipient has a defined role in stability, solubilization, taste masking, or product quality. Any replacement strategy must preserve iodine concentration, osmolality, pH, chemical stability, microbial quality, and patient acceptability.

What is Gastrografin and how is it formulated?

Gastrografin is an oral or rectal water-soluble radiopaque contrast solution used for gastrointestinal imaging. The U.S. label identifies the active ingredients as diatrizoate meglumine and diatrizoate sodium, providing 370 mg/mL of organically bound iodine. The product is hyperosmolar and is administered undiluted or diluted according to the imaging procedure and patient population (Bracco Diagnostics Inc., 2018).

Component	Function in the formulation	Commercial relevance
Diatrizoate meglumine	Ionic iodinated contrast agent	Determines iodine load, radiopacity, osmolality, and much of the product’s safety profile
Diatrizoate sodium	Ionic iodinated contrast agent	Supports iodine concentration and solution properties
Edetate disodium	Chelating agent	Controls trace-metal catalyzed degradation and supports stability
Polysorbate 80	Surfactant and solubilization aid	Supports uniformity and physical stability
Sodium saccharin	High-intensity sweetener	Improves oral acceptability without adding substantial bulk
Water for injection	Vehicle	Determines sterility, conductivity, impurities, and final concentration

The formulation is an aqueous, sterile, high-iodine solution. It is not a lipid emulsion, suspension, polymeric delivery system, or depot product. That limits the value of complex excipient platforms but creates opportunities in solution stability, packaging, taste, and manufacturing efficiency.

What excipients are protected by the Gastrografin formulation?

The named excipients are established pharmaceutical ingredients with broad supplier availability. The principal commercial protection is likely to reside in formulation know-how, specifications, process controls, packaging, and regulatory documentation rather than in proprietary ownership of the excipients themselves.

Edetate disodium

Edetate disodium is a chelating agent. In an iodinated contrast formulation, it can reduce the impact of trace metal contamination on color, degradation, or long-term stability. The commercial value lies in controlling metal impurities and validating the minimum effective concentration.

Potential supplier opportunities include:

• Low-metal pharmaceutical-grade edetate disodium
• Lot-to-lot trace-metal certification
• Supply from qualified secondary manufacturers
• Customized impurity profiles for high-ionic-strength solutions
• Stability packages supporting regulatory submissions

A substitute chelator would require comparative stability data. Replacing edetate disodium with another chelating agent could alter pH, compatibility, toxicology, or regulatory status.

Polysorbate 80

Polysorbate 80 is used as a nonionic surfactant and solubilization aid. Although Gastrografin is an aqueous solution, the surfactant may help maintain formulation uniformity and control interactions involving the iodinated components or packaging.

Key risks include peroxide formation, aldehyde impurities, hydrolysis, and batch variability. These risks have driven increased pharmaceutical scrutiny of polysorbate raw materials in sterile products.

Commercial opportunities include:

• Low-peroxide polysorbate 80
• Controlled fatty-acid composition
• Improved oxidation specifications
• Pharmaceutical-grade material with tighter impurity controls
• Stabilized supply in single-use or small-volume manufacturing
• Analytical packages for peroxide, acid value, water, and fatty-acid composition

A lower-impurity polysorbate 80 may offer a more realistic regulatory path than complete surfactant replacement. Removing polysorbate 80 could simplify the formulation, but it would require evidence that physical stability, assay uniformity, container compatibility, and shelf life remain acceptable.

Sodium saccharin

Sodium saccharin is a taste-masking excipient. Gastrografin’s high osmolality and ionic composition can make oral administration unpleasant. Sodium saccharin provides sweetness at low concentration and avoids the microbial and caloric burden associated with sugars.

Potential formulation strategies include:

• Alternative high-intensity sweeteners
• Blended sweetener systems
• Flavor systems compatible with iodine-containing solutions
• Premixed patient doses
• Palatability products supplied separately for hospital use

The main barriers are taste equivalence, chemical compatibility, pediatric acceptability, and labeling. A replacement sweetener could introduce new toxicological or regional regulatory requirements. A flavoring change may be commercially attractive but would likely require comparative human-factors or palatability data.

Water for injection

Water for injection is the dominant vehicle and a major manufacturing control point. The formulation requires validated control of bioburden, endotoxin, conductivity, total organic carbon, and particulate matter.

Commercial opportunities include:

• Contract manufacturing with sterile liquid capability
• High-throughput compounding and filling
• Regional production hubs
• Packaging in lower-cost polymer containers
• Automated dilution and dose-preparation systems
• Improved supply continuity for hospitals

The product’s high iodine and high osmotic load make container-closure compatibility important. Extractables, leachables, adsorption, seal integrity, and light exposure must be assessed for any packaging change.

What formulation patents protect Gastrografin?

Gastrografin is a legacy contrast product, and its active ingredients and core excipient system are long-established. The current commercial position is unlikely to depend on an unexpired composition-of-matter patent covering diatrizoate or the basic Gastrografin formulation.

IP category	Likely current significance	Commercial assessment
Diatrizoate composition of matter	Low	Legacy active ingredient; basic compound protection is not the main barrier
Core excipient combination	Low to moderate	May have historical patent or know-how coverage, but practical value is limited if expired
Manufacturing process	Moderate	Sterile processing, impurity control, filtration, filling, and scale-up can create know-how barriers
Container closure	Moderate	Compatibility and shelf-life data can delay substitution
Method of use	Low to moderate	Procedure-specific use may be relevant, but it does not necessarily block an equivalent product
Trademark and branding	Moderate	Brand recognition can support hospital procurement and physician familiarity
Regulatory dossier	High practical relevance	Equivalence, stability, validation, and manufacturing data are essential for market entry

Gastrografin is not generally viewed as a current Orange Book patent-exclusivity asset. FDA Orange Book analysis should still be performed for the relevant NDA and any approved alternatives because patent listings, regulatory exclusivity, and product-specific approval status can change (U.S. Food and Drug Administration, n.d.-a).

When does Gastrografin lose exclusivity?

The principal exclusivity period for Gastrografin has effectively passed. The product is a mature contrast medium, and market access is more likely to be controlled by regulatory approval, manufacturing capability, quality systems, and supply agreements than by remaining regulatory exclusivity.

The relevant commercial timeline is:

Milestone	Strategic implication
Historical approval and commercialization	Established safety, clinical use, and hospital familiarity
Expiration of legacy patent rights	Opens the field to equivalent products and alternative suppliers
Mature generic and contract-manufacturing environment	Shifts competition toward price, quality, and reliability
Current hospital purchasing cycles	Creates opportunity for approved alternatives and secondary suppliers
Future formulation changes	May create new data and patent opportunities, but not restore broad exclusivity

A manufacturer seeking approval should focus on the applicable FDA pathway for a diatrizoate oral or rectal contrast product, including reference-product selection, sameness or equivalence requirements, chemistry, manufacturing and controls, stability, sterility, labeling, and post-approval commitments.

What FDA regulatory issues affect a Gastrografin alternative?

Gastrografin is regulated as a drug product and contrast agent. A competing product must establish quality and clinical performance appropriate to its proposed pathway. The critical parameters include:

• Iodine concentration
• Diatrizoate meglumine-to-diatrizoate sodium ratio
• Assay and related substances
• pH
• Osmolality
• Viscosity
• Appearance and color
• Particulate matter
• Sterility and bacterial endotoxins
• Container-closure integrity
• Extractables and leachables
• In-use stability after dilution or opening
• Shelf life under labeled storage conditions

A formulation that changes the sweetener, surfactant, chelator, flavor, or container may require additional comparability work. For an oral product, palatability can affect adherence to imaging protocols. For rectal use, viscosity, delivery volume, retention, and mucosal tolerability become more important.

What commercial opportunities exist in Gastrografin excipients?

Generic or alternative-source Gastrografin

The largest opportunity is an approved equivalent or alternative-source product. Hospitals often value supply security because contrast media shortages can disrupt imaging schedules. A supplier with validated sterile liquid production, reliable iodine sourcing, and competitive pricing could target institutional contracts.

The commercial proposition should emphasize:

• Equivalent iodine concentration
• Consistent product quality
• Reliable fill-finish capacity
• Multiple package sizes
• Stable pricing
• Shorter regional supply chains
• Emergency allocation capability

Excipient supply

Excipient suppliers can target the formulation’s quality-sensitive inputs rather than compete on commodity price alone. Polysorbate 80 with controlled peroxide levels and edetate disodium with low trace-metal content have the clearest technical differentiation.

A supplier package could include:

1. Pharmaceutical-grade material
2. Tight impurity specifications
3. Lot-release analytical data
4. Stability and compatibility studies
5. Regulatory support documentation
6. Dual-source manufacturing

Palatability and administration systems

Taste is a practical weakness of hyperosmolar oral contrast products. A hospital-ready administration platform could combine Gastrografin or an equivalent with:

• Premeasured dilution kits
• Oral dosing cups
• Compatible flavor sachets
• Patient-specific dose labels
• Pediatric administration aids
• Digital protocol instructions for radiology staff

The strongest commercial approach is likely to keep the approved contrast formulation unchanged while improving preparation and administration. This reduces regulatory risk relative to changing the drug product itself.

Packaging and dose presentation

Hospitals may value ready-to-use or procedure-specific presentations. Opportunities include:

• Single-patient bottles
• Unit-dose cups
• Tamper-evident closures
• Large-volume bottles for radiology departments
• Pre-diluted presentations
• Packaging optimized for low residual volume
• Barcoded inventory and automated dispensing

Packaging changes must preserve sterility, iodine concentration, stability, and container-closure integrity.

Which companies are competing in gastrointestinal contrast media?

Gastrografin competes within the broader gastrointestinal contrast market, which includes water-soluble iodinated products and barium-based agents. Relevant competitive factors include radiopacity, aspiration risk, osmolality, taste, cost, availability, and procedural preference.

Competitor category	Examples	Competitive position
Water-soluble iodinated contrast	Diatrizoate-based products	Similar clinical role; competition centers on availability, price, and formulation equivalence
Low-osmolar iodinated agents	Iohexol and related products used off-label or for selected protocols	May offer tolerability advantages in some settings but at different cost and labeling positions
Barium suspensions	Multiple hospital and imaging suppliers	Often lower cost; less suitable where perforation or leakage is a concern
Hospital-compounded dilutions	Institutional preparation	Low direct acquisition cost but higher preparation and quality-control burden
Contract-manufactured alternatives	Regional or generic suppliers	Opportunity created by supply shortages and procurement diversification

Gastrografin’s principal commercial advantages are established use, water solubility, radiographic familiarity, and availability in protocols where extravasation or perforation is a concern. Its main competitive liabilities are high osmolality, taste, and possible tolerability concerns.

How strong is the Gastrografin patent estate?

The patent estate is commercially weak as a barrier to substitution but still relevant to freedom-to-operate review. The product’s durability comes from clinical familiarity, regulatory history, manufacturing validation, and procurement relationships.

A practical strength assessment is:

Asset	Relative strength	Reason
Core active ingredients	Low	Mature compounds with extensive prior art
Basic excipient combination	Low	Conventional ingredients and likely historical disclosures
Manufacturing know-how	Moderate	Sterile high-iodine processing requires specialized controls
Regulatory file and stability data	Moderate to high	Time-consuming to reproduce and critical for approval
Hospital purchasing relationships	Moderate	Can delay uptake of new suppliers
Trademark and brand familiarity	Moderate	Supports physician and radiology-department acceptance
New delivery or palatability technology	Potentially high	Could support new patent filings if technically differentiated

New intellectual-property opportunities may arise from low-peroxide surfactant systems, improved taste-masking combinations, stable pre-diluted formulations, container-closure systems, or automated dose-preparation devices. A patent application would need claims directed to a measurable technical advantage, not merely substitution of one common sweetener or surfactant for another.

What patent litigation and Paragraph IV risks affect Gastrografin?

There is no prominent current Paragraph IV litigation profile associated with Gastrografin comparable to major patented small-molecule blockbusters. Because the product is mature, a new entrant’s litigation exposure is more likely to involve:

• Trademark disputes
• Trade dress or packaging claims
• Manufacturing-process patents
• Formulation patents covering a modified product
• Contract disputes involving supply or distribution
• Regulatory challenges to product equivalence or labeling

A Paragraph IV strategy would be relevant only if an ANDA references an NDA with an unexpired listed patent. For a legacy diatrizoate product, the practical question is whether any current listed patent remains enforceable and relevant to the proposed product. The regulatory record and current Orange Book entries should be reviewed before investment or launch planning (U.S. Food and Drug Administration, n.d.-a).

What generic launch scenarios exist for Gastrografin?

Three launch models are commercially credible.

Low-cost equivalent

This model preserves the established excipient system and competes on price, supply, and institutional contracting. It has the lowest formulation risk.

Premium-quality equivalent

This model uses tighter polysorbate peroxide limits, enhanced edetate specifications, stronger packaging data, and expanded stability support. The product may command a modest premium where supply reliability is critical.

Administration-focused product

This model emphasizes unit-dose packaging, protocol-specific dilution, flavor management, and radiology workflow integration. The drug formulation may remain substantially unchanged while the commercial package improves use efficiency.

Key Takeaways

• Gastrografin is a mature diatrizoate-based gastrointestinal contrast product with no obvious remaining core-molecule exclusivity barrier.
• Its U.S. excipients are edetate disodium, polysorbate 80, sodium saccharin, and water for injection.
• The strongest excipient opportunities are low-peroxide polysorbate 80, low-metal edetate disodium, and palatability systems.
• The best generic strategy is to preserve the established formulation and compete on quality, supply reliability, packaging, and hospital contracting.
• Regulatory and manufacturing execution are more important than basic composition patents.
• Ready-to-use and unit-dose presentations may offer better commercial returns than a heavily modified formulation.
• Any Orange Book, patent, Paragraph IV, or litigation conclusion should be confirmed against the current FDA database and applicable jurisdictional records before launch investment.

FAQs

Is Gastrografin a patented drug?

Gastrografin is a legacy contrast product, and its commercial position is not generally based on a current composition-of-matter patent. Manufacturing, regulatory, trademark, and supply-chain assets are more important.

Can polysorbate 80 be removed from Gastrografin?

Potentially, but removal would require comparative data for physical stability, assay uniformity, container compatibility, shelf life, and product performance. The regulatory pathway would depend on the proposed product and jurisdiction.

Is sodium saccharin essential to Gastrografin?

Sodium saccharin is primarily a palatability excipient. It may be replaced in a new formulation, but the replacement must preserve acceptability, stability, safety, and labeling compliance.

Are barium products direct substitutes for Gastrografin?

They compete in gastrointestinal imaging but are not interchangeable in every procedure. Water solubility, perforation concerns, aspiration risk, imaging protocol, and physician preference affect product selection.

What is the most attractive commercial opportunity around Gastrografin?

The strongest opportunities are an approved alternative product, dual-source excipient supply, low-peroxide polysorbate 80, hospital-ready dose presentation, and supply-resilient sterile manufacturing.

References

1. Bracco Diagnostics Inc. (2018). Gastrografin (diatrizoate meglumine and diatrizoate sodium solution) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.-b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

5. European Medicines Agency. (2019). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. https://www.ema.europa.eu/